Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 5/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31329797 | 0.77 | CYP3A4 (0.39) | CYP2C9CYP2D6CYP3A4 | |
| SCHEMBL31329836 | 0.76 | KMT2A (0.40) | GAASMN1; SMN2POLBMAPTRAB9A | |
| SCHEMBL31329976 | 0.71 | CYP2C9 (0.38) | CYP2C9CYP2D6CYP3A4SMN1; SMN2MAPT | |
| SCHEMBL31329947 | 0.66 | CYP2C9 (0.39) | CYP2C9CYP2D6CYP3A4GAASMN1; SMN2 | |
| SCHEMBL26709437 | 0.66 | LMNA (0.39) | SMN1; SMN2POLBMAPTRAB9A | |
| SCHEMBL26608375 | 0.66 | ALDH1A1 (0.41) | GAASMN1; SMN2POLBMAPT | |
| SCHEMBL31330161 | 0.65 | ALDH1A1 (0.35) | CYP2C9CYP2D6CYP3A4 | |
| SCHEMBL31330045 | 0.63 | KDM4E (0.38) | CYP3A4POLBMAPTRAB9A | |
| SCHEMBL31330044 | 0.63 | KDM4E (0.38) | CYP3A4POLBMAPTRAB9A | |
| SCHEMBL26120639 | 0.62 | CYP2C9 (0.38) | CYP2C9CYP2D6CYP3A4GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024249817-A1 | TRICYCLIC PKMYT1 KINASE INHIBITORS | ENLIVEN INC. (US) | 2024-12-05 | — | — | WO | disclosed |